Drug intelligence / Profile preview

RGB-02

Development stage: Phase 1
Lead developer: Gedeon Richter
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

RGB-02 is a biosimilar of pegfilgrastim developed to prevent chemotherapy-induced neutropenia, particularly in patients with breast cancer receiving myelosuppressive chemotherapy. Pegfilgrastim is a long-acting, pegylated form of recombinant human granulocyte-colony stimulating factor (G-CSF), which stimulates the production of neutrophils from the bone marrow. RGB-02 has been developed and evaluated against the reference product Neulasta, demonstrating therapeutic equivalence in efficacy and safety endpoints in randomized, double-blind, phase 3 clinical trials[1][2][5][6].

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on RGB-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGB-02.

Explore the full profile